环孢素A联合白介素-11对难治性特发性血小板减少性紫癜患者T淋巴细胞亚群及PLT水平变化的影响

Effects of Cyclosporin A Combined with Interleukin-11 on T Lymphocyte Subsets and PLT Levels in Patients with Refractory Idiopathic Thrombocytopenic Purpura

目的 探讨环孢素A联合白介素-11对难治性特发性血小板减少性紫癜（RITP）患者T淋巴细胞亚群及血小板计数（PLT）水平变化的影响.方法 抽取2012年7月—2016年10月82例RITP患者,根据治疗方案分为2组,各41例.对照组给予单纯注射用重组人白介素-11治疗,在此基础上观察组联合环孢素A治疗.统计两组临床疗效及不良反应发生率,对比两组治疗前后T淋巴细胞亚群（CD3＋、CD4＋、CD4＋/CD8＋）、PLT变化及生活质量评分.结果 （1）临床疗效：观察组临床疗效优于对照组,差异有统计学意义（P〈0.05）;（2）T淋巴细胞亚群：两组CD3＋、CD4＋、CD4＋/CD8＋治疗前差异无统计学意义（P〉0.05）,治疗后,观察组CD3＋、CD4＋、CD4＋/CD8＋均高于对照组,差异有统计学意义（P〈0.05）;（3）PLT水平变化：两组PLT水平治疗前比较差异无统计学意义（P〉0.05）,治疗后,两组PLT均有所升高,且观察组高于对照组,差异有统计学意义（P〈0.05）;（4）不良反应：观察组不良反应发生率[17.07％（7/41）vs 9.76％（4/41）]与对照组比较,差异无统计学意义（P〉0.05）;（5）生活质量：两组生活质量评分治疗前比较差异无统计学意义（P〉0.05）,治疗后,观察组生活质量评分高于对照组,差异有统计学意义（P〈0.05）.结论 给予RITP患者环孢素A联合白介素-11治疗,有利于改善患者T淋巴细胞亚群指标,提升PLT,临床效果显著,且具有一定安全性,对改善患者生活质量具有重要意义.

Objective To investigate the effects of cyclosporine A combined with interleukin-11 on T lymphocyte subsets and platelet count （PLT） in patients with refractory idiopathic thrombocytopenic purpura （RITP）. Methods From July 2012 to October 2016, 82 patients with RITP in the hospital were divided into control group and observation group according to the treatment regimen, each group 41 cases. The control group was given simple injection with recombinant human interleukin-11 treatment, on this basis, the observation group combined with cyclosporine A treatment. Clinical efficacy and the incidence of adverse reactions were statistically analyzed between the two groups, and we compared T lymphocyte subsets （CD3＋, CD4＋, CD4＋/CD8＋）, PLT changes and quality of life scores before and after treatment. Results （1）Clinical curative effect： the clinical curative effect of the observation group was better than that of the control group, the difference was statistically significant （P〈0.05）; （2）T lymphocyte subsets： There was no significant difference in CD3＋, CD4＋, CD4＋/CD8＋between the two groups before treatment （P〉0.05）, but after treatment, CD3＋, CD4＋/CD8＋ in the observation group were significantly higher than those in the control group （P〈0.05）; （3）PLT level： There was no significant difference in PLT level between the two groups before treatment （P〉0.05）, but after treatment, the PLT levels of both groups were higher, and the PLT levels of the observation group was higher than those of the control group, the difference was statistically significant （P〈0.05）; （4）Adverse reactions： The incidence of adverse reactions in the observation group [17.07% （7/41） vs 9.76% （4/41）] compared with the control group, the difference was not statistically significant （P〉0.05）; （5）Quality of life： There was no significant difference in the quality of life between the two groups before treatment （P〉0.05）, but after treatment, the observation group was significantly higher than that of the control group （P〈0.05）. Conclusion Treatment of RITP using cyclosporine A combined with interleukin-11 is helpful to improve the T lymphocyte subsets indexes and enhance PLT, The clinical effect is significant, with certain safety, it is of great significance to improve the quality of life of patients.